Evidence map›Paper›PMID 28151455›Full record

ArticleAnnals of Saudi medicine

Association of human leukocyte antigen DRB1 with anti-cyclic citrullinated peptide autoantibodies in Saudi patients with rheumatoid arthritis.

Abdullah Alrogy, Abduallah Dirar, Waleed Alrogy, Hana Fakhoury, Ali Hajeer

Open access · diamondAbstract read
In one paragraph

Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Abdullah Alrogy
Abduallah Dirar
Waleed Alrogy
Hana Fakhoury
Ali HajeerProf. Ali Hajeer, King Saud bin Abdulaziz University for Health Sciences,, Immunology, National Guard Health Affairs,, Riyadh, 11426, Saudi Arabia, T: 966-11-4294047, F: 966-11-2520130, hajeera@ksau-hs.edu.sa, ORCID: orcid.org/0000-0003-2727-9964.
King Saud bin Abdulaziz University for Health Sciences · SAAlfaisal University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe genetic association between human leukocyte antigen (HLA)-DRB1 alleles and the risk of development of autoantibodies has been investigated, but there are few studies from the Gulf region.

objectivesTo investigate the association between the HLA-DRB1 shared epitope and the risk for development of autoantibodies in rheumatoid arthritis (RA) patients in a Saudi population.

designAnalytical cross-sectional study.

settingTertiary care hospital in Riyadh, Saudi Arabia. PATIENTS AND

methodsWe enrolled consecutive Saudi RA patients attending the rheumatology clinic between January and April 2015. Previously published data on HLA typing on unmatched healthy controls were used for comparison. HLA typing was performed using sequence-specific oligonucleotide probes (SSOP). Rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibodies, and antinuclear antibodies (ANA) were also measured. Logistic regression analysis was used to study the autoantibodies as possible explanatory variables for the presence of the HLA-DRB1 shared epitope. MAIN OUTCOME MEASURE(S): The association between the presence of the shared epitope and the risk of developing anti-CCP antibodies, ANA, and RF.

resultsIn 76 patients with RA, carrying the shared epitope was associated with a significantly higher risk of having RA [OR=2.65, 95% CI (1.42-4.94), P=.0009]. However, only HLA-DRB1*04:05 was significantly as.sociated with RA [OR=3.73, 95% CI (1.61-8.96), Pc=.016]. In the logistic regression analysis, only anti-CCP was significantly associated with the shared epitope [OR=14.51, 95% CI (1.53-137.49), P=.02].

conclusionsOur analysis indicates that the presence of the HLA-DRB1 shared epitope is strongly associated with the development of anti-CCP antibodies in Saudi patients with RA. LIMITATIONS: A larger sample size is needed to confirm our finding.

Indexed as

AdultAge of OnsetAntibodies, AntinuclearArthritis, RheumatoidAutoantibodiesCase-Control StudiesCross-Sectional StudiesEpitopesFemaleHLA-DRB1 ChainsHumansMaleMiddle AgedPeptides, CyclicRheumatoid FactorSaudi ArabiaAntibodies, AntinuclearAutoantibodiescyclic citrullinated peptideEpitopesHLA-DRB1 ChainsPeptides, CyclicRheumatoid Factor

Identifiers

PMID28151455
PMCPMC6148974
OpenAlexW2602840102

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.